News Releases

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 8, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of

– Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 7, 2024-- KalVista Pharmaceuticals, Inc.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 6, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that its

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 4, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 43,000 shares of

– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term prophylaxis - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb.

– 94% of attacks required only one dose to achieve primary endpoint - – Further analyses demonstrate efficacy across all levels of attack severity - – Additional safety data reinforces flexibility of dosing - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb.

– Provides entry to UK Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines – – Late-breaking sebetralstat phase 3 data to be presented at the upcoming 2024 American Academy of Allergy , Asthma & Immunology

– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024   – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 15, 2024-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii)